Search results for "subcutaneous"

showing 10 items of 162 documents

Monitoring free serum IgE in severe asthma patients treated with omalizumab

2012

SummaryBackgroundBenefit of treatment with the monoclonal anti-IgE-antibody omalizumab in severe IgE-dependent asthma requires a significant reduction of serum free IgE concentrations. It is unclear if monitoring free serum IgE is clinically meaningful once omalizumab treatment is initiated.MethodsFree IgE and omalizumab serum concentrations were quantified in 22 patients with severe asthma (68% female, 47 ± 11 yrs, mean (±SD) pre-bronchodilator FEV1 62 ± 13%, baseline mean (±SEM) free serum IgE 652 ± 136 ng/ml) treated with omalizumab for 4 months using a Recovery-ELISA.ResultsOmalizumab treatment reduced free serum IgE prior to the second omalizumab injection by 73%, after 16 weeks by 81%…

AdultMalePulmonary and Respiratory MedicineTreatment responsemedicine.medical_specialtySevere asthmaInjections SubcutaneousEnzyme-Linked Immunosorbent AssayOmalizumabOmalizumabTarget rangeAntibodies Monoclonal HumanizedImmunoglobulin EGastroenterologyAnti-asthmatic AgentSerum igeYoung AdultInternal medicinemedicineHumansIn patientAnti-Asthmatic AgentsAgedAsthmabiologybusiness.industryRespiratory diseaseMiddle AgedImmunoglobulin Emedicine.diseaseAsthmaAntibodies Anti-IdiotypicClinical trialTreatment OutcomeFree serum IgEMonoclonalImmunologybiology.proteinFemaleAntibodybusinessmedicine.drugRespiratory Medicine
researchProduct

Quality of life, depression and fatigue in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon bet…

2011

Background: The precise relationships among quality of life, depression, fatigue and cognitive impairment in multiple sclerosis (MS) are complex and poorly understood. Objective: To assess the effects of subcutaneous interferon beta-1a on quality of life, depression and fatigue over 3 years in the COGIMUS study, and to examine the relationship between these outcomes and baseline cognitive status. Methods: COGIMUS was an observational 3-year trial assessing cognitive function in 459 patients with relapsing–remitting MS treated with subcutaneous interferon beta-1a. Results: In total, 331 patients completed the study (168 received interferon beta-1a, 44 µg subcutaneously three times weekly, a…

AdultMaleQuality of lifeLongitudinal studymedicine.medical_specialtyInjections Subcutaneousmultiple sclerosisRelapsing-Remitting Multiple SclerosisInterferon beta 1aYoung AdultMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicQuality of lifeInternal medicinemedicineHumansYoung adultFatigueDepression (differential diagnoses)AgedDepressionbusiness.industryCognitive function; Depression; Fatigue; Interferon beta 1a; Longitudinal study; Quality of life; Relapsing-Remitting Multiple SclerosisMultiple sclerosisCognitive disorderInterferon beta-1aInterferon-betaMiddle Agedmedicine.diseaseClinical trialNeurologyPhysical therapymultiple sclerosis cognition interferon betaFemaleSettore MED/26 - NeurologiaCognitive functionNeurology (clinical)Longitudinal studyCognition DisordersbusinessInterferon beta-1amedicine.drugMultiple Sclerosis Journal
researchProduct

Diet Macronutrient Composition, Physical Activity, and Body Composition in Soldiers During 6 Months Deployment

2018

Abstract Introduction Optimal diet together with good physical fitness maintains readiness and military performance during longer deployments. The purpose of this study was to describe changes in dietary macronutrient and energy intake, total physical activity and body composition during a 6-month deployment in South Lebanon. Furthermore, associations of diet macronutrient intake and physical activity on body composition were also studied. Materials and Methods Forty male soldiers kept a 3-day food diary and their body composition was measured via bioimpedance and ultrasonography. Total physical activity was evaluated by accelerometers in a subgroup of participants. Measurements were conduc…

AdultMaleTotal physical activityWarfareTime FactorsFood diaryPhysical fitnessmacronutrient0211 other engineering and technologiesPhysical activityphysical activity02 engineering and technologynutritional behaviourSubcutaneous fatBody Mass IndexravitsemuskäyttäytyminenEating03 medical and health sciences0302 clinical medicineAnimal sciencesoldiersHumansMacronutrient compositionMedicineravintoaineetsotilaat030212 general & internal medicineta315Exercisekehonkoostumus2. Zero hungerAnalysis of Variancebody composition021110 strategic defence & security studiesbusiness.industryPublic Health Environmental and Occupational HealthNutrientsGeneral MedicineMilitary PersonnelComposition (visual arts)UltrasonographyEnergy Intakebusinessfyysinen aktiivisuusMilitary Medicine
researchProduct

Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of th…

2013

ObjectiveTo assess the effects of subcutaneous (sc) interferon (IFN) -1a on cognition over 5 years in mildly disabled patients with relapsing-remitting multiple sclerosis (RRMS).MethodsPatients aged 18-50 years with RRMS (Expanded Disability Status Scale score ≤4.0) who had completed the 3-year COGIMUS study underwent standardized magnetic resonance imaging, neurological examination, and neuropsychological testing at years 4 and 5. Predictors of cognitive impairment at year 5 were identified using multivariate analysis.ResultsOf 331 patients who completed the 3-year COGIMUS study, 265 participated in the 2-year extension study, 201 of whom (75.8%; sc IFN β-1a three times weekly: 44 µg, n = …

AdultMalemedicine.medical_specialty5 year follow upMultiple SclerosisAdolescentScienceInjections SubcutaneousBrain damageYoung AdultInterferonRecurrenceInternal medicinemedicineHumansIn patientYoung adultCognitive impairmentSex CharacteristicsMultidisciplinarymedicine.diagnostic_testbusiness.industryMultiple sclerosisQRMultiple Sclerosis Subcutaneous interferon β-1a cognitive impairmentMagnetic resonance imagingInterferon-betamedicine.diseaseTreatment OutcomeImmunologyMedicineFemaleSettore MED/26 - Neurologiamedicine.symptomSafetybusinessCognition DisordersInterferon beta-1amedicine.drugResearch ArticleFollow-Up Studies
researchProduct

Autologous fat transfer to the cranio-maxillofacial region: updates and controversies.

2009

Abstract Background Autologous fat grafts have gained popularity among Cranio-Maxillofacial surgeons within the past years. Most publications report favourable outcomes but lack quantifiable evidence of graft survival. Objectives To assess autologous fat transfer for facial asymmetry, and review the literature focusing on current indications, techniques, complications, fat survival and patient satisfaction. Patients and methods Nine patients presented facial asymmetry due to onchological resection, congenital anomaly, or craniofacial traumatism. A total of 11 autologous fat transfers were performed. Four procedures followed the Coleman technique; in the other seven procedures, fat centrifug…

AdultMalemedicine.medical_specialtyAdolescentInjections SubcutaneousAdipose tissueCentrifugationCosmetic TechniquesSuctionAutologous Fat Transferchemistry.chemical_compoundPatient satisfactionPostoperative ComplicationsAdipocytemedicineHumansCraniofacialbusiness.industryAbdominal WallGraft SurvivalMiddle AgedSurgeryCosmetic TechniquesOtorhinolaryngologychemistryAdipose TissueFacial AsymmetryPatient SatisfactionFaceTissue and Organ HarvestingSurgeryGraft survivalFemaleOral SurgerybusinessFacial symmetryJournal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
researchProduct

Botulinum toxin A (Botox) and sweating-dose efficacy and comparison to other BoNT preparations.

2004

Abstract Background Botulinum toxin type A (BoNT/A) is 20–50 times more effective than Botulinum toxin type B (BoNT/B) concerning the treatment of muscular hypercontractions [Sloop, R.R., Cole, B.A., Escutin, R.O., 1997. Human response to botulinum toxin injection: type B compared with type A. Neurology 49, 189–194]. Botulinum toxins block motor nerves as well as autonomic fibres [Rand, M.J., Whaler, B.C., 1965. Impairment of sympathetic transmission by botulinum toxin. Nature 206, 588–591]. Objective Purpose of this study was to analyse the dose dependent reduction of sweating using the BoNT/A preparation Botox® and to compare the results with our earlier results analysing Dysport® [Braune…

AdultMalemedicine.medical_specialtyBotulinum ToxinsTime FactorsInjections SubcutaneousSweatingBotulinum toxin aCellular and Molecular NeuroscienceMedicineHumansBotulinum toxin type BAnhidrosisBotulinum Toxins Type AHypohidrosisDose-Response Relationship DrugEndocrine and Autonomic Systemsbusiness.industryStarchBotulinum toxinSurgerySudomotorDose–response relationshipThreshold doseNeuromuscular AgentsAnesthesiaFemaleNeurology (clinical)medicine.symptombusinessBotulinum toxin typemedicine.drugFollow-Up StudiesAutonomic neuroscience : basicclinical
researchProduct

Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma

2018

Background Mepolizumab has demonstrated favorable safety and efficacy profiles in placebo-controlled trials of 12 months' duration or less; however, long-term data are lacking. Objective We sought to evaluate the long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma (SEA). Methods COLUMBA (Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects, NCT01691859 ) was an open-label extension study in patients with SEA previously enrolled in DREAM (Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma, NCT01000506 ). Patients received 100 mg of subcutaneous mepolizumab every 4 weeks plus standard of care until a protocol-def…

AdultMalemedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsExacerbationInjections Subcutaneous[SDV]Life Sciences [q-bio]ImmunologyEosinophilic asthmaAntibodies Monoclonal HumanizedPlacebos03 medical and health sciences0302 clinical medicineDouble-Blind MethodSurveys and QuestionnairesInternal medicineEosinophiliamedicineHumansImmunology and AllergyIn patientAnti-Asthmatic Agents030212 general & internal medicineAdverse effectRespiratory Tract InfectionsComputingMilieux_MISCELLANEOUSAsthmabusiness.industryMiddle Agedmedicine.diseaseAsthma3. Good healthEosinophils[SDV] Life Sciences [q-bio]Treatment Outcome030228 respiratory systemAsthma Control QuestionnaireBronchitisFemaleInterleukin-5businessMepolizumabmedicine.drug
researchProduct

Testosterone administration increases leukocyte-endothelium interactions and inflammation in transgender men

2021

Objective To evaluate the effect of testosterone treatment on metabolic and inflammation parameters and leukocyte-endothelium interactions in transgender men (TGM). Design Prospective observational study. Setting University hospital. Patient(s) One hundred fifty-seven TGM. Intervention(s) Administration of testosterone undecanoate (1,000 mg, intramuscular) every 12 weeks. Main Outcome Measure(s) Endocrine parameters, adhesion molecules (vascular cell adhesion molecule-1, intercellular cell adhesion molecule-1, and E-selectin), proinflammatory cytokines interleukin-6, and tumor necrosis factor alpha were evaluated in serum before and after treatment using Luminex’s xMAP technology. In additi…

AdultMalemedicine.medical_specialtyEndotheliumInjections Subcutaneousmedicine.medical_treatmentInflammationTransgender PersonsProinflammatory cytokineYoung AdultInternal medicineHuman Umbilical Vein Endothelial CellsLeukocytesHumansMedicineTestosteroneProspective StudiesCell adhesionCells CulturedTestosteroneInflammationbusiness.industryCell adhesion moleculeObstetrics and Gynecologymedicine.anatomical_structureCytokineEndocrinologyReproductive MedicineAndrogensTumor necrosis factor alphaEndothelium VascularInflammation Mediatorsmedicine.symptombusinessCell Adhesion MoleculesFertility and Sterility
researchProduct

Acute inflammatory response in the subcutaneous versus periprosthethic space after incisional hernia repair: an original article.

2014

BACKGROUND: The acute inflammatory response following mesh implantation has been often evaluated in vitro and in animal models. The aim of this study was to evaluate the acute inflammatory response near the prosthesis in human by analysing some inflammatory indicators.METHODS: We used a cohort of twelve male patients affected by midline incisional hernia, who were admitted for surgical mesh repair. A suction drain was placed between the mesh and rectal muscles whereas, the other one was placed between the subcutaneous tissue and the oblique external sheath. The acute inflammatory response was analyzed by measuring the production of interleukin [IL]-1, IL-10, IL-1ra, C-Reactive Protein (CRP)…

AdultMalemedicine.medical_specialtyIncisional herniamedicine.medical_treatmentAcute Disease; Adult; Biomarkers; C-Reactive Protein; Cytokines; Follow-Up Studies; Hernia Ventral; Herniorrhaphy; Humans; Inflammation; Male; Middle Aged; Surgical Mesh; Postoperative Complications; Medicine (all)InflammationProsthesisProsthesisFollow-Up StudiePostoperative ComplicationsDrain fluidmedicineHumansCytokineHerniorrhaphyInflammationbiologybusiness.industryMedicine (all)C-reactive proteinAlbuminInflammatory responseGeneral MedicineBiomarkerMiddle AgedSurgical Meshmedicine.diseaseHernia repairHernia VentralSurgerySettore MED/18 - Chirurgia GeneraleSurgical meshmedicine.anatomical_structureC-Reactive ProteinAcute Diseasebiology.proteinCytokinesHernia repairSurgeryPostoperative Complicationmedicine.symptombusinessBiomarkersSubcutaneous tissueHumanFollow-Up StudiesResearch ArticleBMC surgery
researchProduct

Sources of human plasma cyclic AMP. Examinations before and after beta 2 adrenergic stimulation.

1981

Plasma cyclic AMP was measured in different vessels in seventeen volunteers before and after stimulation with terbutaline. Differences between arterial blood and blood from the hepatic vein, right ventricle, inferior vena cava and a cubital vein could not be demonstrated. Only in the renal vein was the concentration of cyclic AMP decreased. Our results indicate that cyclic AMP is not generated from any specific isolated organ and that changes in cyclic AMP after subcutaneous injection of terbutaline reflect a general influence of this drug.

AdultMalemedicine.medical_specialtyInjections SubcutaneousTerbutalineStimulation030204 cardiovascular system & hematology030226 pharmacology & pharmacyBiochemistryInferior vena cava03 medical and health sciences0302 clinical medicineAdrenergic stimulationInternal medicineCyclic AMPTerbutalineMedicineHumansVeinAgedbusiness.industryBiochemistry (medical)Cell BiologyGeneral MedicineAdrenergic beta-AgonistsMiddle AgedStimulation Chemicalmedicine.anatomical_structureEndocrinologymedicine.veinVentriclecardiovascular systemArterial bloodRenal veinbusinessmedicine.drugThe Journal of international medical research
researchProduct